Recombinant Proteins Market

Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development, Biopharma Production, Research, Diagnostics), End User (Biotech, CROs) & Region - Global Forecasts to 2027

Report Code: BT 7839 Nov, 2022, by marketsandmarkets.com

The global recombinant proteins market in terms of revenue was estimated to be worth $1.4 billion in 2022 and is poised to reach $2.4 billion by 2027, growing at a CAGR of 11.4% from 2022 to 2027. Growth in the recombinant proteins market is primarily driven by factors such as the rise in the collaboration between academics and the pharmaceutical industry, the high prevalence of major infectious diseases and genetic disorders, as well as government investment in life-science research activities. Emerging markets in Asian countries, as well as the rising focus on personalized medicines and protein therapeutics, are other factors expected to offer robust growth opportunities for players in the recombinant proteins market. In contrast, labor-intensive and low-yield production may restrict market growth to a certain extent.

Recombinant Proteins Market

To know about the assumptions considered for the study, Request for Free Sample Report

Recombinant Proteins Market Dynamics

Drivers: Patent expiry of biologics

The growth of the recombinant proteins market corresponds with the growth in the life science and biopharmaceutical industries, as these industries are significant end users for recombinant protein products. The growth in the end user base has compelled several companies to launch new products and invest in the recombinant proteins market. The pharmaceutical industry is currently witnessing the expiration of blockbuster mAbs. For instance, patents for Inlyta, Tykerb, Lucentis, and Atrovent HFA are set to expire in 2020, while those for Remicade and Zevalin expired in 2018 and 2019, respectively. To address this issue, several global pharmaceutical manufacturers are employing various strategies to enhance research activities. These measures are likely to increase the number of drug discovery programs to develop therapeutic antibodies, especially mAbs, which are further creating opportunities for the recombinant proteins market.

Restraints: Declining cost of recombinant proteins

The concept of Price erosion can be defined as the following as a large number of players that enter a niche market and offer similar products without any differentiation, thus crowding the market with less innovative and competitively priced products. During price erosion, the price of such products in the particular market is observed to decline continuously, which then declines the market growth. New technological advacments in the field of recombinant protein manufacturing process have changed the older trend, resulting in higher yield and lower cost of finished products, which permits the production of such proteins on an industrial scale and opens the door for small players who competitively price products without innovation and thus restrain the market growth.

Opportunities: Rising focus on personalized medicine and protein therapeutics

Developing personalized medicine includes the integration of several biotechnologies, such as cell and gene therapies, recombinant proteins, and vaccines, as they play a vital part in the personalization of treatment. Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practices and is changing the way many diseases are identified, classified, and treated. The demand for recombinant protein therapeutics, including hormones, vaccines, monoclonal antibodies, blood factors, and therapeutic enzymes, has also increased over the last few years. Recombinant protein therapeutics have found high recognition for their potential in treating various kinds of diseases, and their demand has increased significantly in recent years owing to the increasing prevalence of chronic diseases. Recombinant proteins are known as highly potent medicines that are safe from off-target side effects, and it takes a shorter time to develop than small molecules.

Challenges: Protein aggregation into inclusion bodies hampering the production of soluble recombinant proteins with proper biological function

Escherichia coli is one of the organisms of choice to produce recombinant proteins. Its use as a cell factory is well-established, and it has become the most popular expression platform. The high-level expression of recombinant protein in Escherichia coli often results in an aggregation of the expressed protein molecules into inclusion bodies. Retrieving active recombinant protein from inclusion bodies is often a long and time-consuming process. The formation of inclusion bodies in bacterial hosts possess a major challenge for the large-scale recovery of bioactive proteins. The process of obtaining bioactive protein from inclusion bodies is labor-intensive, and the yields of recombinant protein are often low. Such challenges in the manufacturing of recombinant proteins affect the market negatively.

Growth factors and chemokines segment dominated the recombinant proteins market in 2021.

Based on product, the recombinant proteins market is classified into growth factors and chemokines, structural proteins, kinase proteins, regulatory proteins, membrane proteins, recombinant metabolic enzymes, adhesion molecules and receptors, immune response proteins, and other recombinant proteins. Growth factors and chemokines commanded the largest share of the recombinant proteins market in 2020. The large share of the growth factors and chemokines segment can be attributed to its major role in for research in field such as cancer, Covid-19, cell culture, neurobiology, transplantation, stem cell research, HIV/AIDS, and wound healing. They also help in orchestrating both innate and adaptive immune responses. Cytokines are gradually being used as adjuvants in the development of vaccines, such as interleukin-2.

The biologics segment to witness the highest CAGR during the forecast period.

Based on type, the drug discovery & development market is segmented into biologics, vaccines, and cell & gene therapy. Biologics accounted for the largest share of the drug discovery & development application for the recombinant proteins market and is also expected to witness the highest CAGR during the forecast period. This is attributed to the growing use of biologics to treat various diseases such as cancer, anemia, chronic kidney disease, autoimmune diseases, diabetes, growth deficiency, and other serious disorders, as well as a strong development pipeline for recombinant protein-based biologics.

Recombinant Proteins Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for recombinant proteins market in 2020.

The recombinant proteins market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America was the largest regional segment of the overall market, followed by Europe. The large share of North America in the global market is attributed to the availability of funding for R&D, government initiatives for R&D in the pharmaceutical industry, the high incidence of chronic & genetic diseases, the growing adoption of life science techniques in research & academia, the large presence of major pharmaceutical and biotechnology companies, and the use of analytical instruments in drug discovery and development.

Recombinant Proteins Market Key Players

The prominent players operating in this market include Thermo Fisher Scientific, Inc.  (US),  R&D Systems (US), Abcam plc (UK), Merck KGaA (Germany), and Proteintech Group, Inc. (US)

Recombinant Proteins Market Report Scope

Report Metric 

Details 

Market Revenue in 2022

$1.4 billion

Estimated Value by 2027

$2.4 billion

Growth Rate

poised to grow at a CAGR of 11.4%

Largest Share Segments

Growth Factors and Chemokines & Biologics

Market Report Segmentation

Product, Application, End User & Region

Growth Drivers

  • Rise in the collaboration between academics and the pharmaceutical industry
  • High prevalence of major infectious diseases and genetic disorders
  • Government investment in life-science research activities

Growth Opportunities

  • Emerging Economies
  • Rising focus on personalized medicine and protein therapeutics
  • Increasing focus on biomarker discovery

Geographies covered

North America, Europe, APAC, MEA, and Latin America

This report categorizes the global recombinant proteins market into the following segments and subsegments:

By Product

  • Growth Factors and Chemokines
  • Immune Response Proteins
  • Structural Proteins
  • Membrane Proteins
  • Kinase Proteins
  • Regulatory Proteins
  • Recombinant Metabolic Enzymes
  • Adhesion Molecules and Receptors
  • Other Recombinant Proteins (include viral antigens and other proteins that participate in the vital cellular role of cell migration, survival, and regulation of immune responses to apoptosis, Alzheimer’s disease, tumor cell phenotypes, neuroinflammation, and autoimmune diseases)

By Application

  • Drug Discovery & Development
    • Biologics
    • Vaccines
    • Cell & Gene Therapy
  • Biopharmaceutical Production
  • Biotechnology Research
  • Academic Research Studies
  • Diagnostics
  • Other Applications (Forensic and Cosmetology Applications)

By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations
  • Other End Users [Diagnostic Centers, Laboratories (Hospital-attached Laboratories (Hals) and Independent Diagnostic Laboratories), Forensic Laboratories, and Cosmetic Industry]

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In 2022, Twist Bioscience Corporation (US) signed a licensing agreement under which Abcam plc (UK) to use a proprietary Twist VHH phage library for the antibody discovery, development, and commercialization of diagnostic and research applications.
  • In 2021, Thermo Fisher Scientific Inc. (US) acquired PeproTech, Inc. (US), a company that provides products such as recombinant proteins, including cytokines and growth factors.
  • In 2021, Abcam plc (UK) opened a 100,000 sq-ft site in Boston for flexibility, scale, and capacity in R&D, production, distribution, and customer service in the life science sector
  • In 2020, Bio-Techne Corporation (US) collaborated with Elpiscience BioPharma (China). This collaboration aimed to develop anticancer therapeutics where Elpiscience would have access to Bio-Techne’s wide product portfolio of antibodies for use in the development of preclinical, clinical, and commercial biopharmaceuticals
  • In 2020, Merck KGaA (Germany) collaborated with Donghao Lansheng (Group) Co., Ltd. (China). This collaboration aims to pilot a new import policy in China. It will facilitate Merck for the customs clearance of research materials for biomedical innovation and analytical use.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 32)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
          FIGURE 1 RECOMBINANT PROTEINS MARKET
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
    1.6 LIMITATIONS 
    1.7 STAKEHOLDERS 
    1.8 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 37)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
           2.2.3 GROWTH FORECAST
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS 
 
3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 7 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 8 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION)
    FIGURE 10 RECOMBINANT PROTEINS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 RECOMBINANT PROTEINS MARKET OVERVIEW 
          FIGURE 12 INCREASING GOVERNMENT INVESTMENTS AND RISING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION AND COUNTRY (2022) 
          FIGURE 13 DRUG DISCOVERY AND DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST SHARE IN ASIA PACIFIC MARKET
    4.3 RECOMBINANT PROTEINS MARKET, BY END USER, 2022–2027 
          FIGURE 14 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES TO FORM LARGEST END-USER SEGMENT FOR RECOMBINANT PROTEINS
    4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC SNAPSHOT 
          FIGURE 15 JAPAN TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 16 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising government funding and increasing R&D expenditure in pharmaceutical and biotechnology companies
                                TABLE 1 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022)
                    5.2.1.2 High prevalence of infectious and chronic diseases
                    5.2.1.3 Growing industry-academia collaborations
                    5.2.1.4 Patent expiry of biologics
           5.2.2 RESTRAINTS
                    5.2.2.1 Declining cost of recombinant proteins
                    5.2.2.2 Stringent regulatory scenario
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging economies
                    5.2.3.2 Rising focus on personalized medicine and protein therapeutics
                                TABLE 2 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE
                    5.2.3.3 Increasing focus on biomarker discovery
           5.2.4 CHALLENGES
                    5.2.4.1 Complications in large-scale production
    5.3 PRICING ANALYSIS 
           5.3.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER
                    TABLE 3 PRICE OF RECOMBINANT PROTEINS, BY KEY PLAYER (USD)
           5.3.2 AVERAGE SELLING PRICE TREND
                    TABLE 4 PRICE OF RECOMBINANT PROTEINS: INDUSTRIAL VS. PHARMACEUTICAL
    5.4 STAKEHOLDER ANALYSIS 
          FIGURE 17 RECOMBINANT PROTEINS MARKET: STAKEHOLDER ANALYSIS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 18 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 ECOSYSTEM ANALYSIS
          FIGURE 19 BIOTECHNOLOGY ECOSYSTEM ANALYSIS: RECOMBINANT PROTEINS FORM AN INTEGRAL PART OF BIOTECHNOLOGY
    5.7 REGULATORY ANALYSIS 
           5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 9 RECOMBINANT PROTEINS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 INTENSITY OF RIVALRY
    5.9 TECHNOLOGY ANALYSIS 
    5.10 PATENT ANALYSIS 
           FIGURE 20 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RECOMBINANT PROTEIN PATENTS (JANUARY 2012–OCTOBER 2022)
           TABLE 10 INDICATIVE LIST OF PATENTS IN RECOMBINANT PROTEINS MARKET
    5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 
           TABLE 11 RECOMBINANT PROTEINS MARKET: LIST OF CONFERENCES AND EVENTS
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 21 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF RECOMBINANT PROTEIN PRODUCTS
    5.13 KEY BUYING CRITERIA OF END USERS 
           FIGURE 22 BUYING CRITERIA OF END USERS FOR RECOMBINANT PROTEINS
 
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT (Page No. - 72)
    6.1 INTRODUCTION 
    6.2 GROWTH FACTORS AND CHEMOKINES 
           6.2.1 GROWTH FACTORS AND CHEMOKINES ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
                    TABLE 13 GROWTH FACTORS AND CHEMOKINES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 14 NORTH AMERICA: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 15 EUROPE: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 16 ASIA PACIFIC: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 IMMUNE RESPONSE PROTEINS 
           6.3.1 IMMUNE CHECKPOINT PROTEINS PLAY KEY ROLE IN CANCER IMMUNOTHERAPY
                    TABLE 17 IMMUNE RESPONSE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 18 NORTH AMERICA: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 19 EUROPE: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 20 ASIA PACIFIC: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 STRUCTURAL PROTEINS 
           6.4.1 STRUCTURAL PROTEINS UTILIZED IN CELL CULTURE APPLICATIONS AS ATTACHMENT FACTORS
                    TABLE 21 STRUCTURAL PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 22 NORTH AMERICA: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 23 EUROPE: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 24 ASIA PACIFIC: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 MEMBRANE PROTEINS 
           6.5.1 MEMBRANE PROTEINS REGULATE PROCESSES THAT HELP BIOLOGICAL CELLS SURVIVE
                    TABLE 25 MEMBRANE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 26 NORTH AMERICA: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 27 EUROPE: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 28 ASIA PACIFIC: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 KINASE PROTEINS 
           6.6.1 KINASE PROTEINS PLAY KEY ROLE IN SIGNAL TRANSDUCTION PATHWAYS
                    TABLE 29 KINASE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 30 NORTH AMERICA: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 31 EUROPE: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 32 ASIA PACIFIC: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.7 REGULATORY PROTEINS 
           6.7.1 REGULATORY PROTEINS HELP UNDERSTAND CELL CYCLE REGULATION AND CARCINOGENESIS
                    TABLE 33 REGULATORY PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 34 NORTH AMERICA: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 35 EUROPE: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.8 RECOMBINANT METABOLIC ENZYMES 
           6.8.1 ENZYMES REGULATE PROTEIN INTERACTIONS
                    TABLE 37 RECOMBINANT METABOLIC ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 38 NORTH AMERICA: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 39 EUROPE: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 40 ASIA PACIFIC: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.9 ADHESION MOLECULES AND RECEPTORS 
           6.9.1 CELL ADHESION MOLECULES FACILITATE EXTRACELLULAR MATRIX (ECM) INTERACTIONS
                    TABLE 41 ADHESION MOLECULES AND RECEPTORS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 42 NORTH AMERICA: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 43 EUROPE: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 44 ASIA PACIFIC: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.10 OTHER RECOMBINANT PROTEINS 
           TABLE 45 OTHER RECOMBINANT PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION)
           TABLE 46 NORTH AMERICA: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 47 EUROPE: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 48 ASIA PACIFIC: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 RECOMBINANT PROTEINS MARKET, BY APPLICATION (Page No. - 93)
    7.1 INTRODUCTION 
          TABLE 49 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    7.2 DRUG DISCOVERY AND DEVELOPMENT 
          TABLE 50 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
          TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 54 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
           7.2.1 BIOLOGICS
                    7.2.1.1 Biologics are used to treat cancer, autoimmune diseases, and other serious disorders
                                TABLE 55 RECOMBINANT PROTEIN BIOLOGIC DRUGS
                                TABLE 56 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.2 VACCINES
                    7.2.2.1 Rising incidence of infectious diseases to boost market growth for vaccines
                                TABLE 60 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 61 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 62 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 63 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.3 CELL AND GENE THERAPY
                    7.2.3.1 Stem cell therapy and CAR T-cell therapies have boosted demand for recombinant proteins
                                TABLE 64 RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 65 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 66 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 67 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 ACADEMIC RESEARCH STUDIES 
           7.3.1 RECOMBINANT PROTEINS HAVE APPLICATIONS IN MOLECULAR AND GENE EXPRESSION STUDIES
                    TABLE 68 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 70 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 71 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 BIOPHARMACEUTICAL PRODUCTION 
           7.4.1 RECOMBINANT PROTEINS WIDELY USED FOR DEVELOPMENT OF PROTEIN-BASED DRUGS
                    TABLE 72 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 73 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 74 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 75 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 BIOTECHNOLOGY RESEARCH 
           7.5.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO DRIVE MARKET GROWTH
                    TABLE 76 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 77 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 78 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 79 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 DIAGNOSTICS 
           7.6.1 HIGH SENSITIVITY AND SPECIFICITY OF RECOMBINANT PROTEIN-BASED DIAGNOSTICS TO INFLUENCE MARKET GROWTH
                    TABLE 80 RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.7 OTHER APPLICATIONS 
          TABLE 84 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 85 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 86 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 87 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 RECOMBINANT PROTEINS MARKET, BY END USER (Page No. - 113)
    8.1 INTRODUCTION 
          TABLE 88 RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
    8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 
           8.2.1 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES ARE LARGEST END USERS OF RECOMBINANT PROTEINS
                    TABLE 89 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 90 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 91 EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 92 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 BIOTECHNOLOGY COMPANIES 
           8.3.1 INCREASING NUMBER OF PROJECTS FOR PROTEIN-BASED RESEARCH DRIVING MARKET GROWTH
                    TABLE 93 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 94 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 95 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 96 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 ACADEMIC RESEARCH INSTITUTES 
           8.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH
                    TABLE 97 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 98 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 99 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 100 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 CONTRACT RESEARCH ORGANIZATIONS 
           8.5.1 INCREASING OUTSOURCING OF SERVICES TO CROS DRIVING MARKET GROWTH
                    TABLE 101 RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.6 OTHER END USERS 
          TABLE 105 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 106 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 107 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 108 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 RECOMBINANT PROTEINS MARKET, BY REGION (Page No. - 124)
    9.1 INTRODUCTION 
          TABLE 109 RECOMBINANT PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 23 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT
          TABLE 110 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 111 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 112 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US accounted for largest share of North American market
                                TABLE 115 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2020 VS. FY 2021 (USD BILLION)
                                TABLE 116 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 117 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 118 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 119 US: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 High prevalence of cancer and favorable funding scenario to support market growth
                                TABLE 120 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 121 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 122 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 123 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.3 EUROPE 
          TABLE 124 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 125 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 126 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 127 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany held largest share of European market in 2021
                                TABLE 129 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 130 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 131 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 132 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Government initiatives to drive market growth in UK
                                TABLE 133 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 134 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 135 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 136 UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Infrastructural development and rising life science R&D expected to support market growth
                                TABLE 137 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 138 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 139 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 140 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Life science research investments and favorable funding scenario to drive growth
                                TABLE 141 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 142 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 143 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 144 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Favorable scenario for research initiatives to propel market growth
                                TABLE 145 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 146 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 147 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 148 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 149 ROE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 150 ROE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 151 ROE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 152 ROE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC 
          TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 154 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 155 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 156 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 157 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Advanced healthcare infrastructure to support market growth
                                TABLE 158 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 159 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 160 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 161 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 China to witness highest growth in Asia Pacific market
                                TABLE 162 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 163 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 164 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 165 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Strong biopharmaceutical growth and rising demand for pharmaceuticals are key market drivers
                                TABLE 166 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 167 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 168 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 169 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 170 ROAPAC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 171 ROAPAC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 172 ROAPAC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 173 ROAPAC: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 LATIN AMERICA 
           9.5.1 GROWTH IN BIOPHARMACEUTICAL INDUSTRY TO DRIVE DEMAND FOR RECOMBINANT PROTEINS
                    TABLE 174 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 175 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 176 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 177 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 INCREASING GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR AND GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
                    TABLE 178 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 179 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 180 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 181 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 176)
     10.1 OVERVIEW 
             FIGURE 25 KEY PLAYERS ADOPTED ORGANIC AND INORGANIC GROWTH STRATEGIES BETWEEN 2019 AND 2022
     10.2 MARKET SHARE ANALYSIS 
             FIGURE 26 RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS, 2021 (TOP 4 PLAYERS)
             TABLE 182 RECOMBINANT PROTEINS MARKET: DEGREE OF COMPETITION
     10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 27 REVENUE SHARE ANALYSIS OF PLAYERS IN RECOMBINANT PROTEINS MARKET (TOP 4)
     10.4 COMPANY EVALUATION MATRIX: KEY PLAYERS (2021) 
             10.4.1 VENDOR INCLUSION CRITERIA
             10.4.2 STARS
             10.4.3 EMERGING LEADERS
             10.4.4 PERVASIVE PLAYERS
             10.4.5 PARTICIPANTS
                       FIGURE 28 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2021)
     10.5 COMPANY EVALUATION MATRIX: START-UPS/SMES (2021) 
             10.5.1 PROGRESSIVE COMPANIES
             10.5.2 STARTING BLOCKS
             10.5.3 RESPONSIVE COMPANIES
             10.5.4 DYNAMIC COMPANIES
                        FIGURE 29 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2021)
     10.6 COMPETITIVE BENCHMARKING OF TOP 25 COMPANIES 
             10.6.1 OVERALL FOOTPRINT OF TOP 25 COMPANIES
                        FIGURE 30 FOOTPRINT ANALYSIS OF KEY PLAYERS IN RECOMBINANT PROTEINS MARKET
     10.7 COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 
             TABLE 183 RECOMBINANT PROTEINS MARKET: DETAILED LIST OF KEY START-UPS/SMES
             TABLE 184 RECOMBINANT PROTEINS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
     10.8 COMPETITIVE SCENARIO 
             10.8.1 PRODUCT LAUNCHES AND APPROVALS (2019–2022)
             10.8.2 DEALS (2019–2022)
             10.8.3 EXPANSIONS (2019–2022)
 
11 COMPANY PROFILES (Page No. - 189)
     11.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             11.1.1 BIO-TECHNE CORPORATION
                        TABLE 185 R&D SYSTEMS: BUSINESS OVERVIEW
                        FIGURE 31 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021)
             11.1.2 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 186 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             11.1.3 MERCK KGAA
                        TABLE 187 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021)
             11.1.4 ABCAM PLC
                        TABLE 188 ABCAM PLC: BUSINESS OVERVIEW
                        FIGURE 34 ABCAM PLC: COMPANY SNAPSHOT (2021)
             11.1.5 ABNOVA CORPORATION
                        TABLE 189 ABNOVA CORPORATION: BUSINESS OVERVIEW
             11.1.6 BIOLEGEND
                        TABLE 190 BIOLEGEND: BUSINESS OVERVIEW
             11.1.7 BIO-RAD LABORATORIES, INC.
                        TABLE 191 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             11.1.8 BPS BIOSCIENCE, INC.
                        TABLE 192 BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW
             11.1.9 ENZO LIFE SCIENCES, INC.
                        TABLE 193 ENZO LIFE SCIENCES, INC.: BUSINESS OVERVIEW
                        36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2021)
             11.1.10 GENSCRIPT BIOTECH CORPORATION
                        FIGURE 37 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
             11.1.11 MILTENYI BIOTEC
                        TABLE 195 MILTENYI BIOTECH: BUSINESS OVERVIEW
             11.1.12 PROTEINTECH GROUP
                        TABLE 196 PROTEINTECH GROUP: BUSINESS OVERVIEW
             11.1.13 SINO BIOLOGICAL INC.
                        TABLE 197 SINO BIOLOGICAL INC.: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     11.2 OTHER PLAYERS 
             11.2.1 ACROBIOSYSTEMS
             11.2.2 AVIVA SYSTEMS BIOLOGY CORPORATION
             11.2.3 CELLGENIX GMBH
             11.2.4 ICOSAGEN AS
             11.2.5 NEUROMICS
             11.2.6 PROSPEC-TECHNOGENE LTD.
             11.2.7 PROTEOGENIX
             11.2.8 RAYBIOTECH, INC.
             11.2.9 LAURUS BIO (RICHCORE LIFESCIENCES PVT. LTD.)
             11.2.10 STEMCELL TECHNOLOGIES INC.
             11.2.11 STRESSMARQ BIOSCIENCES INC.
             11.2.12 UNITED STATES BIOLOGICAL
 
12 APPENDIX (Page No. - 238)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the recombinant proteins market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the recombinant proteins market. The secondary sources used for this study include The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), American Medical Association, Associations of Medical Laboratories, National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), press releases, company websites, annual reports, SEC Filings, interviews with experts, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

 

Recombinant Proteins Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Recombinant Proteins Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the recombinant proteins business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global recombinant proteins market based on the product, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall recombinant proteins market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the recombinant proteins market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

An additional five company profiles

Report Code
BT 7839
Published ON
Nov, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Recombinant Proteins Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback